Validation of a claims‐based algorithm to identify cases of ulcerative colitis in Japan

  • Haruei Ogino
    Department of Medicine and Bioregulatory Science Graduate School of Medical Sciences, Kyushu University Fukuoka Japan
  • Hiromu Morikubo
    Center for Advanced IBD Research and Treatment Kitasato University Kitasato Institute Hospital Tokyo Japan
  • Keita Fukaura
    Department of gastroenterology Saiseikai Futsukaichi Hospital Fukuoka Japan
  • Tasuku Okui
    Medical information center Kyushu University Hospital Fukuoka Japan
  • Sean Gardiner
    Inflammation and Immunology Pfizer Inc New York New York USA
  • Naonobu Sugiyama
    Inflammation & Immunology, Medical Affairs Pfizer Japan Inc Tokyo Japan
  • Noritoshi Yoshii
    Inflammation & Immunology, Medical Affairs Pfizer Japan Inc Tokyo Japan
  • Tsutomu Kawaguchi
    Inflammation & Immunology, Medical Affairs Pfizer Japan Inc Tokyo Japan
  • Haoqian Chen
    Center for Pharmacoepidemiology and Treatment Science Rutgers Institute for Health, Health Care Policy and Aging Research New Brunswick New Jersey USA
  • Edward Nonnenmacher
    Center for Pharmacoepidemiology and Treatment Science Rutgers Institute for Health, Health Care Policy and Aging Research New Brunswick New Jersey USA
  • Soko Setoguchi
    Center for Pharmacoepidemiology and Treatment Science Rutgers Institute for Health, Health Care Policy and Aging Research New Brunswick New Jersey USA
  • Naoki Nakashima
    Medical information center Kyushu University Hospital Fukuoka Japan
  • Taku Kobayashi
    Center for Advanced IBD Research and Treatment Kitasato University Kitasato Institute Hospital Tokyo Japan

書誌事項

公開日
2021-11-26
権利情報
  • http://creativecommons.org/licenses/by-nc-nd/4.0/
DOI
  • 10.1111/jgh.15732
公開者
Wiley

この論文をさがす

説明

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background and Aim</jats:title><jats:p>The prevalence of ulcerative colitis (UC) is increasing in Japan. Validated claims‐based definitions are required to investigate the epidemiology of UC and its treatment and disease course in clinical practice. This study aimed to develop a claims‐based algorithm for UC in Japan.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A committee of epidemiologists, gastroenterologists, and internal medicine physicians developed a claims‐based definition for UC, based on diagnostic codes and claims for UC treatments, procedures (cytapheresis), or surgery (postoperative claims). Claims data and medical records for a random sample of 200 cases per site at two large tertiary care academic centers in Japan were used to calculate the positive predictive value (PPV) of the algorithm for three gold standards of diagnosis, defined as physician diagnosis in the medical records, adjudicated cases, or registration in the Japanese Intractable Disease Registry (IDR).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Overall, 1139 claims‐defined UC cases were identified. Among 393 randomly sampled cases (mean age 44; 48% female), 94% had received ≥ 1 systemic treatment (immunosuppressants, tumor necrosis factor inhibitors, corticosteroids, or antidiarrheals), 7% had cytapheresis, and 7% had postoperative claims. When physician diagnosis was used as a gold standard, PPV was 90.6% (95% confidence interval [CI]: 87.7–93.5). PPV with expert adjudication was also 90.6% (95% CI: 87.7–93.5). PPVs with enrollment in the IDR as gold standard were lower at 41.5% (95% CI: 36.6–46.3) due to incomplete case registration.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>The claims‐based algorithm developed for use in Japan is likely to identify UC cases with high PPV for clinical studies using administrative claims databases.</jats:p></jats:sec>

収録刊行物

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ